Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GSK and A*STAR’s Institute of Chemical Engineering and Sciences To Develop New Medicines

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
State-of-the-art laboratory focused on developing new, improved formulations for added patient benefit.

GlaxoSmithKline (GSK) and A*STAR’s Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.

ICES has a long standing relationship with GSK since 2003, and the development of EBFs will further strengthen the relationship between both parties. The collaboration leverages on ICES’ strengths and expertise in synthesis, formulation and process development, as well as GSK’s vast experience in drug candidate selection, optimisation, and product development in novel formulations. The collaboration will enhance ICES’ technical expertise and know-how in drug product formulation, analytical techniques, development and scale up. It will develop a pool of local expertise in specialised formulation for pharmaceutical development in Singapore.

Collaborating with GSK, a global leader in pharmaceuticals and healthcare provides an opportunity for us to further our research and deepen our capabilities in formulation science with skilled scientists and technical expertise. This venture will enable us to develop future scientists and laboratory analysts with the right skills to grow this industry in Singapore” said Dr Keith Carpenter, Executive Director, ICES.

The establishment of a joint partnership between ICES and GSK will position Singapore as a regional centre for drug development for the emerging markets.

This agreement with ICES is perfectly aligned with GSK’s strategic priority of growing a diversified global business, whilst bringing affordable, quality GSK medicines of value to more people who need them. Within GSK’s portfolio of off-patent products, EBFs are an important part of our growth strategy, and our hope is that together with ICES we will create a sustainable, scalable model to meet both specific market conditions and patient requirements,” commented Duncan McKay, Vice President, Emerging Markets & Asia Pacific R&D, GSK.

 “We are pleased that GSK has chosen Singapore as a strategic partner to develop new evidenced-based drug formulations. This is a strong endorsement of Singapore’s scientific talent and capabilities. It also further reinforces Singapore’s offering as the base for companies to generate insights and develop new solutions and market access strategies for the fast growing emerging markets,” said Kevin Lai, Director, Biomedical Sciences, Singapore Economic Development Board.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Unexpected Synergy Between Two Cancer-Linked Proteins Offers Hope for Personalised Cancer Therapy
A team of scientists have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs.
Thursday, August 08, 2013
Singapore Scientists Discover New Drug Targets for Aggressive Breast Cancer
Study has identified genes that are potential targets for therapeutic drugs against aggressive breast cancer.
Monday, July 29, 2013
Genome Institute of Singapore Scientists Discover Molecular Communication Network in Human Stem Cells
Scientists have discovered a molecular network in human embryonic stem cells that integrates cell communication signals to keep the cell in its stem cell state.
Tuesday, July 02, 2013
First Lab-on-Chip Created for the Detection of Multiple Tropical Infectious Diseases
A*STAR and Veredus Laboratories announced the launch of VereTrop(TM) that can identify 13 different major tropical diseases from a single blood sample.
Monday, April 29, 2013
Singapore Scientist Wins Coveted Chen New Investigator Award 2013
Dr Patrick Tan is lauded for his significant contributions to the research on genomic profiles of Asian cancers.
Tuesday, April 23, 2013
A*STAR Scientists Make Groundbreaking Discovery on Stem Cell Regulation
Scientists have identified that precise regulation of polyamine levels is critical for embryonic stem cell (ESC) self-renewal - the ability of ESCs to divide indefinitely - and directed differentiation.
Thursday, March 01, 2012
Cambridge Team First to Grow Smooth Muscle Cells from Patient Skin Cells
This work could lead to new treatments and better screening for cardiovascular disease.
Thursday, January 26, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!